Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZS805 injection in Fabry disease (single-arm, dose-escalation, phase I/II)
CTR20244539Phase 2Active
- Sponsor
- Zhishan Weixin Biotechnology
- Start
- Dec 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ZS805 in Fabry disease (FD), sponsored by Zhishan Weixin Biotechnology. Started Dec 2024; status: active.
02
Drugs
ZS805
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20244539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244539.